FLT3 and acute myeloid leukemia: Post-hoc subgroup analyses showed significantly prolonged OS with CPX-351 in patients with AML with prior CMML or MDS, t-AML, in those who were stratified as favorable/intermediate according to cytogenetic risk classification, and those with FMS-like tyrosine kinase 3 wild-type (FLT3wt) [32].